LXEO
Lexeo TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive Phase 2 topline data combined with a partnership or favorable regulatory pathway could validate the program, extend runway, and produce material upside (consistent with the bull target).
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Trial failure, inability to raise capital on acceptable terms, or adverse regulatory feedback would likely force dilutive financings or shutdown, implying significant downside consistent with the bear target.
Momentum
8
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.22 · Bull $1.95 · Bear $0.61
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-17 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $19.64
Why
Momentum8 · Δ7d +2.0
Value41 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
8
34% active weight
Current posture
7d trendFlat
Δ7d
+2.0
Δ21d
-3.0
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 7.8 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$377.69M
Beta
-
Shares Out
72.99M
P/E (TTM) · Derived
-1.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.06
Rev YoY
-
EPS YoY
+62.7%
Gross Margin
-
Op Margin
-
Net Debt
-$120.13M
Current Ratio
7.40
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology